StockNews.AISignal intelligence
Simulations Plus, Inc. · NASDAQ · Healthcare
Browse public SLP signals with their source context and measured market impact. Open any signal for its permanent analysis page.
SLP's Q4 2025 earnings surpassed expectations despite a decline in revenue. Sales totaled $17.5 million, slightly above estimates but down 6% year-over-year. Adjusted earnings were 10 cents per share, improving from a loss forecast. Fiscal 2026 guidance is stable with earnings expected between $1.03-$1.10. Analyst forecasts indicate potential for recovery amid improving biotech funding.
View signal analysisSLP's Q3 2025 sales of $20.4 million missed estimates by $0.5 million. The company reported a significant net loss of $67.3 million this quarter. Adjusted earnings are down from prior guidance, now forecasted at $0.93 to $1.06. Market analysts expect continued weak demand in the biotech sector. SLP shares fell 25% to $13.10 following the earnings report.
View signal analysisSLP forecasts third-quarter sales of $19-$20 million, below estimates. 2025 sales outlook cut to $76-$80 million from $90-$93 million. Market volatility is impacting demand and causing project delays. Company plans workforce reduction of about 10% to enhance efficiency. Stock price fell 23.2% following the announcements and guidance cuts.
View signal analysis